Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Killing cancer by protecting normal cells

14.11.2014

An anti-cancer drug protects normal cells from radiation damage and increases the effectiveness of radiation therapy in prostate cancer models

Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue.

A new anti-cancer drug, already in clinical development, may help address this issue by protecting normal cells - but not the cancer - from the effects of radiation. The research, published November 14th in Molecular Cancer Therapeutics, further suggests this drug may also be useful in treating accidental exposure to radiation.

"It was a stroke of luck that the drug that most effectively protected normal cells and tissues against radiation also has anti-cancer properties, thus potentially increasing the therapeutic index of radiation therapy," says Ulrich Rodeck, M.D., Ph.D., Professor of Dermatology and Cutaneous Biology and Radiation Oncology at Thomas Jefferson University, and senior author on the study.

Together with first author Vitali Alexeev, Ph.D., Assistant Professor, Dermatology and Cutaneous Biology, Dr. Rodeck and colleagues tested five compounds that were shown to have radiation-protective properties in earlier studies. The researchers gave the mice one of the five compounds a day before and for several days after radiation treatment.

A compound called RTA 408 emerged from this screen as a robust radiation protector and its effect was comparable to the only drug currently approved by the FDA for that purpose. (The approved drug, called amifostine, however, has a number side effects including severe nausea or vomiting that make it an unappealing choice for clinicians.) Sites that are usually most susceptible to radiation damage including the gut and blood cells in the bone marrow were both protected in mice treated with RTA 408.

Using human prostate cancer cells growing in mice, the researchers also showed that RTA 408 did not confer radiation protection to the cancer cells. In fact, when RTA 408 was given alone, without radiation, it also slowed the growth of human prostate cancer transplants in mice. In combination, it further amplified the tumor growth inhibitory effects of radiation.

"It was really exciting to see," says Dr. Rodeck, "that combining radiation and RTA-408 more effectively inhibited tumor growth compared to using either one or the other as single treatment modalities."

Dr. Rodeck and colleagues plan to continue to unravel the molecular underpinnings of these radiation-protective effects in order to understand how exactly this compound works and how its mechanism of action might be improved for clinical applications.

RTS 408 is currently being developed by REATA pharmaceuticals for a number of clinical applications, including a trial currently enrolling patients for a topical form of the drug applied to patients who experience radiation dermatitis.

This work was supported by DoD grant W81XWH-12-1-0477, and a pilot project under National Institute of Health grant U19A1091175 to Dr. Rodeck. Additional support was provided by the Prostate Cancer Foundation and by REATA Pharmaceuticals. One of the authors (Keith Ward) is employed by and has a financial interest in REATA Pharmaceuticals, Inc. The authors report no other conflicts of interest.

For more information, contact Edyta Zielinska, 215-955-5291, edyta.zielinska@jefferson.edu.

About Jefferson -- Health is all we do.

Thomas Jefferson University, Thomas Jefferson University Hospitals and Jefferson University Physicians are partners in providing the highest-quality, compassionate clinical care for patients, educating the health professionals of tomorrow, and discovering new treatments and therapies that will define the future of healthcare. Thomas Jefferson University enrolls more than 3,600 future physicians, scientists and healthcare professionals in the Sidney Kimmel Medical College (SKMC); Jefferson Schools of Health Professions, Nursing, Pharmacy, Population Health; and the Graduate School of Biomedical Sciences, and is home of the National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center. Jefferson University Physicians is a multi-specialty physician practice consisting of over 650 SKMC full-time faculty. Thomas Jefferson University Hospitals is the largest freestanding academic medical center in Philadelphia. Services are provided at five locations -- Thomas Jefferson University Hospital and Jefferson Hospital for Neuroscience in Center City Philadelphia; Methodist Hospital in South Philadelphia; Jefferson at the Navy Yard; and Jefferson at Voorhees in South Jersey.

Article Reference: V. Alexeev, et al., "Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound," Molecular Cancer Therapeutics, doi: 10.1158/1535-7163.MCT-14-0354, 2014

Edyta Zielinska | EurekAlert!

More articles from Life Sciences:

nachricht Water forms 'spine of hydration' around DNA, group finds
26.05.2017 | Cornell University

nachricht How herpesviruses win the footrace against the immune system
26.05.2017 | Helmholtz-Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>